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Abstract 34 
This investigation aimed to explore the effects of inert sugar free drinks described as 35 
either ‘performance enhancing’ (placebo) or ‘fatigue inducing’ (nocebo) on peak 36 
minute power (PMP;W) during incremental arm crank ergometry (ACE).  Twelve - 37 
healthy, non - specifically trained individuals volunteered to take part. A single blind 38 
randomized controlled trial with repeated measures was used to assess for differences 39 
in PMP;W and oxygen uptake, heart rate, minute ventilation, respiratory exchange 40 
ratio, and subjective reports of local (LRPE) and central (CRPE) ratings of perceived 41 
exertion, between three separate, but identical ACE tests. Participants were required 42 
to drink either 500ml of a ‘sports performance’ drink (placebo), a ‘fatigue inducing’ 43 
drink (nocebo), or water prior to exercise. The placebo caused a significant increase in 44 
PMP;W, and a significant decrease in LRPE compared to the nocebo (p=0.01; 45 
p=0.001) and water trials (p=0.01). No significant differences in PMP;W between the 46 
nocebo and water were found. However, the nocebo drink did cause a significant 47 
increase in LRPE (p=0.01).  These results suggest that the time has come to broaden 48 
our understanding of the placebo and nocebo effect and their potential to impact 49 
sports performance. 50 
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Introduction  55 
The placebo effect in sport has only become a subject of regular research enquiry in 56 
the last 10 to 15 years. Despite this slow start, several studies have observed 57 
significant increases in endurance (Clark, Hopkins, Hawley and Burke, 2000) and 58 
strength performance (Maganaris, Collins and Sharp, 2000; Kalasountas, Reed and 59 
Fitzpatrick, 2007) as a result of ingesting a substance with no inherent ability to 60 
produce such a positive effect.  61 
Despite suggestions of its existence in sports science, less is known about the nocebo 62 
effect (Beedie and Foad, 2009), defined as ‘the undesirable effects an individual 63 
experiences after ingesting an inert substance’. However, it is axiomatic to propose 64 
that the nocebo effect may be just as relevant to sports performance (Maganaris et al., 65 
2000; Kalasountas et al., 2007).  For example, Maganaris et al. (2000) and 66 
Kalasountas et al. (2007) reported significant decreases in performance when subjects 67 
were told that their improvements in weightlifting were the result of a sham anabolic 68 
steroid. Such a suggestion assumes the nocebo effect is simply reversing a positive 69 
outcome, which may underestimate its true potential to negatively impact 70 
performance if studied in isolation.  71 
Testing this hypothesis, Beedie, Coleman and Foad (2007) observed a trend towards 72 
reduced speed in consecutive sprint trials in a group that held a negative belief about 73 
an inert substance. In comparison they found a significant linear trend of greater 74 
speed with each successive experimental trial in a group that had been informed that 75 
the same substance enhanced performance. Compared to mainstream medicine an 76 
understanding of the placebo/nocebo remains in its infancy. However, a greater 77 
understanding of the placebo/nocebo effect, and their application to various sports and 78 
exercise modalities will supplement current understanding of these factors reportedly 79 
influencing athletic performance.  Prior research and theory from the pain sciences 80 
suggest that expectations influence the placebo/nocebo effect (Stewart-Williams and 81 
Podd, 2004; Pollo et al., 2001; Fillmore and Vogel-Sprott, 1992). Illustrating this 82 
point, Clark et al. (2000) reported the greatest changes in power during a 40km cycle 83 
time trial, in a group that were told their performance would be increased by 84 
carbohydrate administration, regardless of whether they eventually received 85 
carbohydrate or placebo.  86 
 87 
Contrary to this, ambiguity surrounding the proposed treatment may produce results 88 
that are incongruent with expectation (Foad, Beedie and Coleman, 2008). More 89 
specifically, Foad et al. (2008) reported that the effects of caffeine were greatest when 90 
participants believed that they had not ingested caffeine as opposed to when they 91 
believed they had. The mere presence of potential placebo and/or a placebo design 92 
made individuals question treatment allocation and thus had a contradictory effect on 93 
the anticipated outcome. Despite the link between expectation and the placebo effect, 94 
few studies have assessed this experimentally in the sports science domain (Pollo, 95 
Carlino and Benedetti, 2008).  A better understanding here may help to clarify the 96 
relationship between the effect an individual expects to experience, and the actual 97 
experience itself.  A meta-anlysis by Berdi, Koteles, Szabo, and Bardos (2011) has 98 
established that further research is needed to determine the importance of the placebo 99 
effect on sports performance and that a more balanced placebo design is required 100 
along with comparing a no treatment group.  Therefore, the current investigation 101 
aimed to explore the effects of inert sugar free drinks described either as ‘performance 102 
enhancing’ (Sports performance drink - placebo) or ‘fatigue inducing’ (nocebo) or 103 
plain water on peak minute power (PMP;W) during an incremental arm crank 104 
ergometry (ACE) test to volitional exhaustion. This dynamic has not been explored 105 
previously and as incremental tests are used extensively in applied and clinical 106 
settings it is a valid predictor of performance and health respectively (Bassett and 107 
Howley, 2000).  It was hypothesised that the sports performance and fatigue inducing 108 
drink would significantly increase and decrease PMP;W respectively, compared to a 109 
comparison test using water.   110 
 111 
 112 
Methods 113 
 114 
Participants 115 
Twelve, healthy, non-specifically trained, able-bodied male individuals volunteered to 116 
take part in the study (mean ±SD age: 25.3 ± 4.4 years; weight: 80.5 ± 16.9 kg; 117 
height: 178.8 ± 4.4 cm).  Participants volunteered to take part on the basis that they 118 
would received the outcome of the study but no financial incentive was provided. 119 
Participants were injury free at the time of data collection and provided written 120 
informed consent.  University Ethics Committee approval for the study’s 121 
experimental procedures was obtained and followed the principles outlined in the 122 
Declaration of Helsinki.   123 
 124 
Design:  125 
 126 
Participants were required to perform three separate (one week apart), incremental 127 
tests using a Monark arm crank ergometer (Monark Inc, London UK) to determine 128 
PMP;W.  Thirty minutes prior to each test, participants were required to drink either 129 
500ml of water, or the same volume of a ‘sports performance’ (placebo) or ‘fatigue 130 
inducing’ drink (nocebo). These drinks were in fact identical commercial sugar - free 131 
drinks that had no known physiological effect on performance. The study was 132 
performed in a randomized cross over design and was single blinded.  133 
 134 
Prior to the relevant test, a standardized written script was handed to the participant’s. 135 
These highlighted how the drinks worked to increase (sports performance drink) or 136 
decrease (fatigue inducing drink) PMP;W. Participants were told that the water trial 137 
was being used as a comparison.  138 
 139 
 140 
Procedures: 141 
 142 
 143 
A ramp protocol was used whereby power output (watts) increased every two minutes 144 
(Price et al., 2011; Smith et al., 2001). Participants initially exercised for two minutes 145 
at 0W. After this, the workload increased to 50W, and then by 20W every two 146 
minutes. Participants were required to complete the test using a constant speed of 70 147 
rev. min
-1
 until volitional exhaustion.  148 
 149 
PMP;W was calculated using the value(s) of the workload experienced during the 150 
final minute of the test. If a participant performed their final workload at 150W for a 151 
minute, their PMP was 150W. However if a participant performed at different 152 
workloads, the calculation by Smith et al. (2004) was used to determine PMP;W.  153 
 154 
Oxygen consumption (VO2) respiratory exchange ratio (RER), carbon dioxide 155 
production (VCO2) and minute ventilation were analysed using an online breath-by-156 
breath analysis system (Cosmed Quark b
2
 metabolic analyse-gas analysis) and 157 
averaged over the final 15 seconds of each workload, and over the final 15 seconds of 158 
the test for peak responses. Heart rate (HR) was monitored using a heart rate monitor, 159 
and measured at the same intervals (Price, Bottoms, Smith and Nicholettos, 2011).  160 
 161 
Fingertip blood samples were collected at volitional exhaustion and analysed for 162 
blood lactate concentration (Analox GM7, Surrey, UK). Ratings of perceived exertion 163 
for local working muscles (LRPE) and cardio-respiratory (CRPE) components of 164 
effort perception (Borg Scale) were recorded during the last 15 seconds of each 165 
exercise stage and at volitional exhaustion (Price et al., 2011).  166 
  167 
After the third test, participants were asked to identify (using a Likert scale from 1 to 168 
10) the degree to which they expected the sports performance drink would positively 169 
impact their performance (1 being not at all, 5 to some extent and 10 being very much 170 
so), and the degree to which they expected the nocebo drink would decrease their 171 
performance (1 being very much so, 5 to some extent and 10 being not at all). 172 
Following this, they were informed about the true nature of the experiment and why 173 
deception was a fundamental component. 174 
 175 
Statistical analysis  176 
All data was analysed using SPSS version 20.0. The Shapiro-Wilk statistic confirmed 177 
that the normal distribution assumption was met for all variables.  Therefore, a 178 
repeated measures one-way ANOVA was used to assess differences in PMP:W 179 
between trials, post blood lactate values, and expectation scores (Likert scale).  A 180 
two-way ANOVA for repeated measures was used to assess the main effect of time, 181 
group, and time - group interactions for physiological variables: heart rate, VO2, 182 
VCO2, RER, VE, and subjective ratings of central and local RPE values. Appropriate 183 
post-hoc analyses were conducted using a Bonferroni correction to control for type I 184 
error. Partial effect sizes were calculated using an η2. Spearman’s rank correlation co-185 
efficients were used to explore the relationship between the extent to which the 186 
participants expected (likert score) the two drinks would increase (placebo)/ decrease 187 
(nocebo) their performance, and how their PMP;W subsequently increased/ decreased 188 
compared to the water trial. Data are presented as mean  standard deviation in 189 
tables and figures. Significance was set at p<0.05. 190 
 191 
 192 
Results  193 
PMP;W 194 
 195 
Ten out of 12 participants improved on the placebo trial compared to the water trial 196 
(Table 1), whereas only 5 out of 12 participants produced a lower PMP;W on the 197 
nocebo trial compared to the water trial.   198 
 199 
***Table 1 near here*** 200 
 201 
A significant difference in PMP;W was found between the three conditions (F2, 22 202 
=5.8: p= .001, η2= .347, with the highest PMP;W values occurring in the placebo trial 203 
(Figure 1). Post - hoc analyses demonstrated a significant increase in PMP;W using 204 
the placebo compared to water (p= .013), and the nocebo (p= .044). No significant 205 
difference in PMP; W was found between the nocebo and water (p= 1.00). 206 
 207 
Physiological measurements 208 
A significant increase in LRPE with exercise intensity was observed (main effect of 209 
time (F5, 30 =130.0: p <.001, η
2
= .956). Furthermore, significant differences in LRPE 210 
values between the conditions (main effect of condition (F2, 12 =4.81: p =.03, η
2
= 211 
.445).  Post - hoc analyses demonstrated significantly lower LRPE for placebo 212 
compared to water (p =.004), and significantly greater LRPE values for nocebo 213 
compared to water (p = .01), and finally significantly higher values for nocebo 214 
compared to placebo (p = .001; Table 2).  There was no significant interaction 215 
between condition and time (F10, 60 =1.76: p = .09, η
2
= .270). 216 
 217 
HR, VO2, VCO2 RER and subjective scores of central ratings of perceived exertion 218 
increased significantly with exercise intensity as they all demonstrated significant 219 
main effects for time (F5, 15 =39.0: p < .001, η
2
= .929, F5, 20 =33.4: p < .001, η
2
= .893, 220 
F5, 20 =9.5: p < .001, η
2
= .759, F5, 15 = 11.99: p < .001, η
2
= .800 and F5, 25 =60.4: p < 221 
.001,  η2= .930 respectively). However, no significant condition and time * condition 222 
interactions were found. Post blood lactate levels did not differ between the three 223 
conditions (F2, 22 = 1.897: p = .174, η
2
= .147; Table 2).  224 
 225 
***Table 2 near here*** 226 
 227 
A significant difference between the three Likert scores (expectation) was found (F2,22 228 
= 14.2: p < .001, η2= .563). Post hoc tests revealed significantly greater scores for 229 
placebo compared to water (p < .001), and for nocebo compared to water (p < .001), 230 
with no significant difference observed between the placebo and nocebo (p = .80).   231 
 232 
 233 
Spearman’s rank correlation co-efficients revealed a significant correlation (rho= 0.85 234 
; p < .001) between individuals who had the greatest increase in PMP;W (compared to 235 
water) and those who had the highest expectation of the placebo drink (Likert). 236 
Similarly, a significant weak correlation was found between individuals who had the 237 
largest decrease in performance (compared to water) and individuals with the highest 238 
expectation of the nocebo drink (Figures 1 and 2 respectively).  239 
 240 
***Figures 1 and 2 near here*** 241 
242 
Discussion 243 
Consistent with the hypothesis, the current investigation demonstrated a significant 244 
increase in PMP;W when participants ingested a placebo drink compared to water. 245 
Furthermore, a significant decrease in LRPE compared to water and nocebo was 246 
observed. Consequently, participants increased their power output, whilst 247 
simultaneously reporting less discomfort in their arms.  248 
 249 
These data add to an increasing number of studies that have reported improvements in 250 
performance as a result of ingesting a placebo aid. The percentage increases in 251 
performance here (6.3%; percentage increase in PMP;W compared to the water and 252 
nocebo trial) are both lower (Pollo et al., 2008; Kalasountas et al., 2007; Ariel and 253 
Saville, 1972) and higher than values previously recorded (Foad et al., 2008; Beedie 254 
et al., 2007; McClung and Collins, 2007; Beedie et al., 2006; Clark et al., 2000; 255 
Maganaris et al., 2000). However, methodological variances between the studies, 256 
including the mode of exercise and its outcome measure, and the duration of the study 257 
make direct comparisons difficult. The present study used a water trial as a no 258 
treatment group to more accurately assess the extent of the placebo effect as 259 
suggested by Berdi et al. (2011). The collective data do suggest that the placebo can 260 
exert its effect across several exercise modalities and protocols of different durations.  261 
 262 
Contrary to the hypothesis the nocebo drink failed to cause a significant decrease in 263 
performance. This asymmetry between the placebo and nocebo may be due to 264 
discrepancies in the participant’s appreciation of the two drinks. That is, participants 265 
better understood that a drink could increase, rather than decrease performance. 266 
Statistical tests suggested that there was no significant difference in the expectation 267 
assigned to the two drinks (Likert scale). This finding may highlight a possible 268 
limitation of the Likert scale and it may not be sensitive enough to determine 269 
differences, compared to qualitative equivalents. In addition, the likert scale was 270 
given after the test and may therefore not completely reflect their expectation prior to 271 
the test. In future the scale should be presented prior to the test to more accurately 272 
measure the expectation of the drink.  It may also be reasonable to suggest that a 273 
fatigue inducing drink may not be the best method of activating a nocebo response.  274 
 275 
It is important to highlight an observation from the current investigation that provides 276 
evidence for the nocebo. Evidence for a nocebo response was the response of LRPE 277 
with the nocebo causing a significant increase in LRPE compared to water and the 278 
placebo. These data add to previous data that suggest that expectations alter somatic 279 
perception (Caspi and Bootzin, 2002; Lundh, 1987; Ross and Olson, 1981) by causing 280 
individuals to selectively attend to an increase or decrease in their symptoms (seen in 281 
the present study as an increase or decrease in LRPE).  282 
  283 
The present study used an incremental VO2 peak test. This design was chosen because 284 
it is a valid and objective test of performance in the exercise domain (Bassett and 285 
Howley, 2000). The potential to impact performance during this mode of exercise has 286 
implications for a number of different individuals such as kayakers. Due to the 287 
smaller muscle mass of the arms in comparison to lower body exercise, a different 288 
response may have been expected to that previously shown with lower body exercise.  289 
The current study used well - defined objective physiological measures to identify a 290 
maximal effort to limit potential suggestions that the ‘placebo effect’ was simply 291 
attributable to participants trying harder (Kalasountas et al., 2007).  292 
 293 
The current investigation used a Likert scale, in order to identify the relationship 294 
between the expectation of a change in performance and those individuals with who 295 
had the greatest change in PMP;W. This assessment tool was easy to use, and 296 
significant correlations were found between individuals with the highest expectations 297 
of the placebo and nocebo drink and individuals who subsequently had the greatest 298 
changes in PMP; W compared to the water trial.  However, this scale failed to identify 299 
any individual factors that may have increased an individual’s expectations of the two 300 
drinks, possibly because it was presented after the test rather than prior to the test. 301 
This may be particularly important since not all participants experienced a placebo/ 302 
nocebo effect. Qualitative data may have provided more information about individual 303 
experiences, and should feature in future research (Mengshoel, 2012).  304 
 305 
These data, together with previous work, suggests that the placebo and nocebo have 306 
the capacity to influence sport performance. Further work should be focused on how 307 
coaches and clinicians can develop techniques to harness the placebo, whilst avoiding 308 
a potential nocebo response. From a theoretical standpoint, further research into the 309 
placebo/nocebo may also broaden our understanding of how the brain governs 310 
peripheral processes that influence sports performance. For example, it has been 311 
suggested that fatigue during exercise involves a complex interaction between a 312 
number of peripheral physiological systems and the brains evaluation of the 313 
‘exercising body’ (Gibson et al., 2006; Lambert, Gibson and Noakes, 2005). Thus, 314 
whilst peripheral factors such as metabolite accumulation are important, the brain 315 
orchestrates the final decision, based on all relevant factors, including for example, 316 
the knowledge that a drink has been consumed that is ‘sport enhancing’. This may 317 
manifest in a situation like that seen in the current investigation where an increase in 318 
PMP’;W is observed despite there being no significant difference between the groups 319 
for objective physiological markers. 320 
 321 
In conclusion, the current investigation reported a significant increase in PMP; W 322 
together with a decrease in LRPE, following the ingestion of an inert ‘sports 323 
performance’ drink. The current study failed to report a significant nocebo effect on 324 
PMP;W. However, a significant increase in LRPE was observed compared to water 325 
and the placebo drink. These results suggest that the time has come to broaden our 326 
understanding of the placebo and nocebo effect and their potential to impact sports 327 
performance. Future work should supplement quantitative measures of physical 328 
function, with qualitative interviews to better understand the factors that influence an 329 
individual’s response.  More specifically, participants can be asked to report their 330 
sensations during the placebo and nocebo conditions.  This data can then be 331 
referenced against objective physiological measures to provide a wider picture of the 332 
human response to the consumption of performance enhancing or inhibiting drinks.  333 
Ultimately, a better understanding here may enable clinicians and coaches to develop 334 
techniques to harness the placebo and or avoid the nocebo and with it open a 335 
potentially very large and important door.  336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
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Tables: 433 
434 
Table 1: PMP;W values for the three trials * significant difference between tests (p 435 
<0.05). 436 
Participant 
Water 
PMP;W (watts)  
Nocebo 
PMP;W (watts)   
Placebo 
PMP;W (watts) 
1 138 136 148 
2 130 130 130 
3 145 130 155 
4 90 90 110 
5 110 117 114 
6 145 130 150 
7 158 145 162 
8 153 150 158 
9 130 150 150 
10 110 113 110 
11 125 125 130 
12 130 130 130 
Mean  SD 130  20 129 17 137 19* 
 437 
438 
Table 2. Mean ±SD for the physiological variables. *+#denotes significant 439 
differences. 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
 449 
 450 
 451 
 452 
 453 
 454 
 455 
 456 
457 
 Peak Value 
(water) 
Peak Value 
(Nocebo) 
Peak Value 
(placebo) 
VO2 (l.min
-1
) 2.95  0.99 2773  397 2.62  0.98 
VCO2 (l.min
-
1
) 
3.72  0.13 2.67  0.88 3.23  0.12 
RER   1.19  0.1 1.14  0.1 1.29  0.1 
VE (l.min
-1
) 120  28  127  15 123  4 
HR 
(beats.min
-1
) 
168  16  159  21  167  20  
CRPE (borg 
scale) 
18  2 16  2 17  2 
LRPE (borg 
scale) 
19 ± 1*
#
 20 ± 1*
+
 18 ± 1
#+
 
Blood lactate 
(mmol) 
9.0  2.5 8.2  2.1 10.0  2.8  
List of Figures: 458 
Figure 1: Relationship between the increase in PMP:W (placebo drink compared to 459 
the water trial) and the expectation of an increase in performance (Likert score) (r 460 
=0.95; p<0.001) 461 
Figure 2: Relationship between the decrease in PMP;W (nocebo drink compared to 462 
the water trial) and the expectation of a decrease in performance (Likert score) 463 
(r=0.97; p <0.001) 464 
 465 
 466 
